Cooper I A, Ding J C, Adams P B, Quinn M A, Brettell M
Am J Hematol. 1979;6(4):387-98. doi: 10.1002/ajh.2830060411.
The role of leukapheresis was explored in the management of anaemia and thrombocytopenia complicating the accumulation of lymphoid cells in patients with chronic lymphocytic leukaemia and lymphoma. The aim of this study was to determine the efficiency of this procedure in correcting these complicating features and to assess the length of response and the clinical well being of the patients. Twenty such patients with either chronic lymphocytic leukaemia or lymphocytic lymphoma were studied using a Continuous Flow Cell Separator (Aminco Celltrifuge). All had persistent significant anaemia and/or thrombocytopenia prior to the institution of leukapheresis. The procedure was carried out on alternate days until significant reduction in total circulating lymphoid cells had been achieved, an average of 2.9 x 10(11) cells being removed on each occasion. Thirteen of the twenty patients showed a significant elevation of both haemoglobin and platelet level concomitant with reduction in lymphoid cells. A reduction in organomegaly was also observed. These patients were classified as "responders," but the other patients failed to show correction of the haematologic parameters. This procedure permitted a number of responder patients to receive more specific treatment but in some it obviated the necessity for any further management for up to 12 months. Surface marker studies were also carried out on the lymphocytes of these patients. The patients who showed the best response to leukapheresis had cells characteristic of those seen in chronic lymphocytic leukaemia. The reduction of cells (82%) was greater in those who responded to this treatment than in the non-responder group (72%). The procedure was well tolerated by all patients and overall provided a long-term control of disease which outweighed the initial cost incurred.
探讨了白细胞单采术在治疗慢性淋巴细胞白血病和淋巴瘤患者因淋巴细胞蓄积而并发的贫血和血小板减少症中的作用。本研究的目的是确定该程序在纠正这些并发症方面的有效性，并评估缓解期的长短以及患者的临床状况。使用连续流式细胞分离器（Aminco Celltrifuge）对20例慢性淋巴细胞白血病或淋巴细胞淋巴瘤患者进行了研究。所有患者在进行白细胞单采术前均存在持续性显著贫血和/或血小板减少症。该程序每隔一天进行一次，直至循环淋巴细胞总数显著减少，每次平均去除2.9×10¹¹个细胞。20例患者中有13例血红蛋白和血小板水平显著升高，同时淋巴细胞减少。还观察到脏器肿大减轻。这些患者被归类为“反应者”，但其他患者的血液学参数未得到纠正。该程序使一些反应者患者能够接受更特异性的治疗，但在一些患者中，长达12个月无需进一步治疗。还对这些患者的淋巴细胞进行了表面标志物研究。对白细胞单采术反应最佳的患者的细胞具有慢性淋巴细胞白血病患者细胞的特征。对该治疗有反应的患者的细胞减少率（82%）高于无反应组（72%）。所有患者对该程序耐受性良好，总体上提供了长期的疾病控制，超过了最初产生的费用。
